- Rating
- 2
- Confidence
- 2
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
The paper evaluates neural compression methosd for EEG, iEEG, and ECG signals. The authors argue that global fidelity metrics such as PRD or RMSE offer limited insight into the error distribution across particular frequency bands, that may affect downstream physiological analysis. They demonstrate this with a band-swapping experiment on CHB-MIT seizure detection at 64× compression. They therefore utilize a bandwise PRD as a main diagnostic to compare quantizers and encoder-decoder variants and report that lookup-free quantizers beat codebook-based ones and a symmetric convolutional encoder-decoder is the best tradeoff between accuracy and cost.
Based on these findings, the authors introduce their codec BioSQ, which pairs a symmetric convolutional encoder-decoder with Residual Binary Spherical Quantization (RBSQ). RBSQ is a multi-stage residual extension of BSQ trained with per-stage entropy regularization and followed by arithmetic coding of the binary indices. They evaluate reconstruction fidelity of BioSQ against BrainCodec and classical compression baselines on four public datasets at compression ratios from 4x to 128x, with BioSQ reporting lower PRD than the baselines. They also demonstrate better downstream task performance of BioSQ compared against BrainCodec. The authors claim that BioSQ is the first neural codec effective across both brain and cardiac signals.
Critical strengths
1. Relevant, underexplored problem. Long-term EEG, iEEG and ECG monitoring produces large data volumes, and neural compression of biosignals has received far less attention than audio or images. Testing which audio-codec design choices transfer to physiological signals is a worthwhile question.
2. Clinically motivated evaluation. The paper convincingly demonstrates that global PRD can mask band-specific distortions. The band-swap experiment (Fig. 2) shows that perturbations with similar effects on global PRD can affect downstream seizure detection very differently.
3. Broad empirical coverage. The evaluation spans four public datasets, three modalities (scalp EEG, iEEG, ECG), compression ratios from 4× to 128×, and three downstream task types (seizure detection, motor imagery, QRS detection). This provides a useful evaluation across different physiological signals.
4. Systematic comparison of quantizers and architectures. The authors investigate RVQ, ERVQ, SNAC, BSQ, RFSQ, and RBSQ, along with alternative encoder-decoder designs. Both successful and unsuccessful architectural choices are reported. The appendix further includes useful analyses of codebook utilization, reconstruction limits, frequency-band specialization, and RBSQ stage configurations.
5. Simpler training. BioSQ does not require adversarial training and generally matches or outperforms BrainCodec, especially at high compression ratios, where downstream gains are largest.
Critical weaknesses
1. Frequency awareness is limited to evaluation and model selection. Despite the title, BioSQ does not explicitly incorporate frequency-dependent compression mechanisms, such as band-weighted losses or frequency-adaptive bit allocation. The frequency-aware analysis is valuable, but the final codec is not itself explicitly frequency-adaptive.
2. The "first neural codec across brain and cardiac signals" claim is overstated. NeuroRVQ (arXiv:2510.13068) reconstructs EEG, ECG and EMG with RVQ tokenizers and releases ECG weights. PhysioOmni (arXiv:2504.19596) and Hypnos (arXiv:2606.09605) also tokenize EEG and ECG. Though these works do not report compression ratio and PRD, so a narrower claim may hold, but they should be cited and discussed.
3. Frequency-aware evaluation is missing from the final quantitative comparison. Although the paper argues that global PRD can mask frequency-localized errors, band-wise PRD is used only to compare BioSQ variants internally, while the main comparison against prior methods (Fig. 4) rely solely on global PRD. No band-wise comparison against BrainCodec is provided, even though it could explain the cases where BrainCodec achieves lower global PRD but BioSQ performs better downstream.
4. Limited statistical reporting. The results include means and medians but no confidence intervals, variability across training runs, or significance tests. This is particularly relevant for the smaller improvements in Table 1 and the BCI IV-2a downstream results. More information about random seeds and experimental variability is needed.
5. Minor presentation and reproducibility issues.
- The architecture is called SEANet in Fig. 1 but described as 2D (K,1) convolutions in Sec. 3.
- F = 16 (Sec. 4) is undefined.
- The classical baseline is labeled NLSPIHT in the CHB-MIT and SWEC-ETHZ panels of Fig. 4 but SPIHT in the BCI IV-2a panel, while Sec. 4.2 lists only NLSPIHT.
- In Figs. 3 and 14 (top row), the proposed quantizer is labeled “BioSQ” rather than “RBSQ”. BioSQ denotes the full system, while the other legend entries are quantizers.
- Figs. 3 and 14 do not state the dataset used, or whether band PRD values are means or medians and over which subjects or segments.
Questions for authors
1. Given the motivation and title, did the authors explore making the codec itself frequency-aware, for example through band-weighted reconstruction losses or frequency-adaptive bit allocation?
2. How do you reconcile the claim of being the first neural codec effective across brain and cardiac signals with NeuroRVQ, PhysioOmni and Hypnos? Please cite them and consider comparing against NeuroRVQ's public ECG tokenizer.
3. Could the authors provide band-wise PRD comparisons between BioSQ and BrainCodec on the EEG and iEEG datasets, particularly at operating points where BrainCodec has lower global PRD but BioSQ achieves better downstream performance?
4. Is a single model trained across all modalities and compression ratios, or are separate models trained per dataset and compression ratio? Could the authors also provide random seeds or variability estimates?
5. Please reconcile the abstract's "up to 25%" with the conclusion's 12%, 2% and 22%, and state the dataset and compression ratio at which the "81%" reduction is obtained.
4 comments
It must be noted that all three works are designed to be tokenizers for foundation models, rather than biosignal compressors. Therefore, the design choices and evaluation results are notably different from ours, and the models are much larger in both parameters and training dataset. By our calculation from their published configurations, the nominal rate of the ECG tokenizer of NeuroRVQ is about 2,000 bit/s, similar to BioSQ at CR 4×, while that of Hypnos is about 44 bit/s, below BioSQ at CR 128× (about 64 bit/s).
Following the Reviewer's suggestion, we evaluate the publicly released EEG tokenizers of NeuroRVQ and Hypnos on the same CHB-MIT test windows as BioSQ and BrainCodec, and compute the PRD from their reconstructions. Both tokenizers are used as released, without retraining. Both models low-pass the input at 45 Hz, so we report the PRD against the original signal and the PRD after band-passing both signals to 0.5-45 Hz.
| Codec | bit/s per channel | PRD, full band | PRD, 0.5-45 Hz |
|---|---|---|---|
| BioSQ (CR 128×) | 64 | 43.5 | 38.5 |
| Hypnos | 88 | 48.8 | 33.1 |
| BioSQ (CR 64×) | 128 | 30.3 | 26.8 |
| NeuroRVQ | 416 | 48.6 | 27.0 |
| BioSQ (CR 16×) | 512 | 10.3 | 7.6 |
In the 0.5-45 Hz band, NeuroRVQ at 416 bit/s reaches the PRD that BioSQ reaches at 128 bit/s, and Hypnos at 88 bit/s is comparable to BioSQ at the same rate. On the full band both tokenizers are worse, since they do not reconstruct frequencies above 45 Hz. We emphasize that these models are tokenizers for foundation models: they were trained on different data and sampling rates, and were not designed for fidelity at a fixed bit rate. We therefore read this comparison as a reference point and not as a claim of superiority. We add the results and the evaluation protocol to Appendix I.
For ECG, the publicly released NeuroRVQ tokenizer (2,080 bit/s per lead), evaluated on a sample of 80 MIT-BIH windows shared with BioSQ and BrainCodec, reaches a PRD of 1.5%. This is similar to the 1.6% of BioSQ at CR 64× (128 bit/s), which uses 16 times fewer bits, and higher than the 0.55% of BioSQ at CR 16× (512 bit/s). We include this comparison in Appendix I.
To further strengthen the generality of BioSQ, we also add electromyography (EMG) as a fourth modality. We use the NinaPro DB2 dataset [4] and train one BioSQ and one BrainCodec model per compression ratio, with the same pipeline and configuration as for the other datasets. The Table below shows the median PRD over held-out subjects at the same nominal rate, without arithmetic coding, as in our answer to Reviewer T4sm (W1).
| Dataset | Codec | 4× ↓ | 16× ↓ | 64× ↓ | 128× ↓ |
|---|---|---|---|---|---|
| NinaPro DB2 (EMG) | BrainCodec | 2.37 | 16.01 | 56.94 | 72.22 |
| NinaPro DB2 (EMG) | BioSQ | 4.50 | 14.70 | 53.16 | 70.09 |
As on SWEC-ETHZ and MIT-BIH, BrainCodec is better at 4×, and BioSQ is better from 16× on. We read this as evidence that the approach extends to EMG, and add the results to Appendix K.
Finally, we now better clarify the role of BioSQ in the Introduction as specifically targeting compression in real-world clinical and industry application, rather than dataset tokenization.
W3. Frequency-aware evaluation
We show the results of the quantitative frequency-aware evaluation in Sections 5.1 and 5.2. Specifically, Figure 3 (top row) compares band-wise PRD on CHB-MIT between RVQ (the quantizer of BrainCodec), and RBSQ with the same encoder and decoder. RBSQ's PRD is lower in every band at 4×, 16× and 64×. Following the Reviewer's suggestion, we now add the same comparison for the iEEG dataset, shown below at CR 4× and 16× and added to Appendix G in full. Band and global PRD are computed in the same way, on the same test windows for both codecs, so the global values may differ slightly from the per-subject medians of Figure 4.
| PRD (%) | Global | δ | θ | α | β | γ-low | γ-high |
|---|---|---|---|---|---|---|---|
| CR 4×, BrainCodec | 0.7 | 0.1 | 0.2 | 0.4 | 0.9 | 2.9 | 7.1 |
| CR 4×, BioSQ | 1.4 | 0.4 | 0.5 | 1.0 | 1.9 | 4.9 | 11.2 |
| CR 16×, BrainCodec | 4.5 | 1.0 | 1.3 | 2.6 | 6.7 | 21.8 | 47.1 |
| CR 16×, BioSQ | 4.2 | 0.6 | 0.8 | 1.6 | 3.5 | 16.2 | 54.4 |
At CR 4×, BrainCodec's PRD is lower in every band, in line with Figure 4. Errors up to β are below 2%, and both codecs reach the F1 of the original signal (Figure 5). At CR 16×, the global PRD is similar, while BioSQ is better from δ to γ-low, most clearly in β, and worse in γ-high, which holds a small part of the signal energy. While the per-band analysis does improve our understanding of the compression performance, we cannot claim that it fully explains this behaviour. We now state the dataset and the aggregation in the captions of Figures 3 and 14.
See the rest of the response in the following comment.
W4. Statistical reporting
Following the Reviewer's suggestion, we now add subject-level statistics for Figure 4. The Table below shows the median PRD over held-out subjects, the median paired difference between BioSQ and BrainCodec with its 95% bootstrap interval and the p-value of a paired Wilcoxon signed-rank test.
| Dataset | CR | BrainCodec | BioSQ | Difference | p |
|---|---|---|---|---|---|
| CHB-MIT | 4× | 6.26 | 1.20 | −4.9 [−5.7, −2.7] | <0.001 |
| CHB-MIT | 16× | 15.04 | 10.28 | −5.0 [−6.0, −3.5] | <0.001 |
| CHB-MIT | 64× | 33.58 | 30.34 | −3.6 [−4.0, −3.0] | <0.001 |
| SWEC-ETHZ | 4× | 0.78 | 1.39 | +0.5 [+0.4, +0.6] | <0.001 |
| SWEC-ETHZ | 16× | 4.20 | 4.25 | +0.2 [−0.2, +0.3] | 0.34 |
| SWEC-ETHZ | 64× | 16.49 | 15.99 | −0.8 [−1.7, −0.4] | <0.001 |
| SWEC-ETHZ | 128× | 30.93 | 27.81 | −2.7 [−3.2, −2.5] | <0.001 |
BioSQ is significantly better on CHB-MIT at all compression ratios, and on SWEC-ETHZ from 64×. BrainCodec is better on SWEC-ETHZ at 4×, and the two are tied at 16×. Moreover, we also add the same analysis to the downstream task on BCI IV-2a. The Table below shows the mean accuracy over held-out subjects, as in Figure 5, and the mean paired difference in accuracy points with its 95% interval across subjects.
| CR | BrainCodec | BioSQ | Difference |
|---|---|---|---|
| 4× | 73.7 | 73.6 | −0.03 [−0.31, +0.24] |
| 16× | 73.2 | 73.3 | +0.08 [−0.79, +0.95] |
| 64× | 70.7 | 72.4 | +1.72 [−2.20, +5.64] |
| 128× | 64.2 | 65.7 | +1.59 [+0.70, +2.48] |
The two codecs are equivalent up to 16×, with differences below 0.1 points. We now add these results to Appendix J and better clarify the positioning of BioSQ with respect to the SoTA.
W5. Minor presentation issues
We thank the Reviewer for helping us improve our manuscript. We now address each and update the manuscript accordingly:
- SEANet is a 1D convolutional encoder-decoder. In Section 3 we write its convolutions as 2D with kernel (K,1) over the channel and time axes. This is equivalent to applying the same 1D convolution over time to each channel independently, as stated in Section 4. We now mention this explicitly in Section 3.
- F is the number of channels of the first convolution. It doubles after each downsampling layer up to a maximum of 256. We now define it in Section 4.
- The classical baseline indeed differs between datasets. In CHB-MIT and SWEC-ETHZ it is NLSPIHT [1], with results taken from [2]. For BCI IV-2a no NLSPIHT results are available, and the panel shows the SPIHT results reported by [3] together with AAC. We now use a label that makes this distinction clear, correct the caption of Figure 4, and list both baselines in Section 4.2.
- The Reviewer is indeed correct, in the top row of Figures 3 and 14 the encoder-decoder is fixed and only the quantizer changes, so the proposed quantizer should be labeled RBSQ. We now relabel it. BioSQ in the bottom row denotes the full system, RBSQ with the SEANet encoder-decoder.
- Figures 3 and 14 show CHB-MIT. Band PRD is the PRDb of Eq. 3 computed over all test windows, so it is neither a mean nor a median across subjects. We now state the dataset, the aggregation and the test subjects in the captions.
Q1. Frequency-based losses
We address this in W1.
Q2. Related works
We address this in W2.
Q3. Band-wise PRD comparisons
We address this in detail in W3.
Q4. Per-modality model
We train a separate model for each dataset and each compression ratio, using the same pipeline and configuration for each. Each model is evaluated on held-out subjects that are disjoint from its training subjects. We now make this explicit in Section 4. Variability across held-out subjects is reported in our answer to W4. Training one model per dataset and compression ratio over multiple random seeds is computationally expensive. These runs are in progress, and we will add the results once they finish.
Q5. Manuscript improvements
We thank the Reviewer for pointing out this improvement. The 81% is the reduction of the median PRD on CHB-MIT at CR = 4×, from 6.26% for BrainCodec to 1.20% for BioSQ. We now state the dataset and the compression ratio in the Abstract and in the Conclusion. The Abstract and the Conclusion report different values for the same quantity, the downstream gain over BrainCodec. The relative improvement over BrainCodec at 128× is 12% (seizure detection, CHB-MIT), 5% (seizure detection, SWEC-ETHZ), 2% (motor-imagery classification) and 22% (QRS detection). We now replace “up to 25%” with “up to 22%”.
[1] Xu, Gaowei, et al IEEE Signal Processing Letters (2015). [2] Carzaniga, Francesco, et al ICLR (2025). [3] Nguyen, Binh, et al. IJCNN (2017). [4] Atzori, Manfredo, et al Scientific Data 1, 140053 (2014).
We greatly appreciate the time and effort dedicated by the Reviewer to improve our work. As the discussion period is coming to an end, we kindly ask the Reviewer to acknowledge whether we have successfully addressed their outstanding concerns. We remain available to further discuss any remaining question or weakness in our work.
We thank the Reviewer for highlighting the importance of the problem which is the focus of this work, and for appreciating our broad and thorough evaluation.
Following the Reviewer's suggestions, we now clarify the practical relevance of our frequency aware evaluation, and improve the positioning of our paper with respect to the existing literature. We also add EMG as an additional modality to strengthen the generality of our model, and improve the clarity of our manuscript.
We address each point in detail below.
W1. Frequency-aware pipeline
We thank the Reviewer for raising this point, which allows us to better clarify the novelty of BioSQ and especially of its frequency-based analysis. As described in the manuscript, the entire development pipeline for BioSQ was guided by the evaluation on biologically relevant frequency bands rather than on the global reconstruction quality, with the end goal of improving reconstruction of real-world morphological features (see Appendix D) and classification performance.
This frequency-aware setup directly allowed us to identify highly relevant and novel effects, such as the decoupling between global reconstruction quality (PRD) and downstream classification accuracy (see Section 5.1). We now better highlight the value of this contribution in the Introduction and in Section 5.1. The frequency-based analysis also guided our choice of quantizer, which settled on an augmented version of BSQ, RBSQ, which achieved the best reconstruction fidelity at lower, more biologically relevant frequencies, in exchange for lower fidelity at higher frequencies (see Figure 3 at CR=64).
Following the Reviewer's suggestion, we now directly manipulate the band fidelity of BioSQ during training by adding a band-restricted spectral term to the training loss with weight λB (full details in Appendix H). As the gradient balancer rescales the gradient of each term at the output, the band term receives a share λB/(2+λB) of the gradient norm: 33% for λB=1 and 50% for λB=2. We report the results for β and γ-low on CHB-MIT at CR=16 below:
As expected, differential weighting helps the targeted frequency band at the cost of the others. Such a solution may be attractive for a task-specific compressor, but the band worth favouring depends on the task. Indeed, in seizure detection (Fig. 2), the largest gain comes from β. We now repeat the same band-swap analysis on motor imagery (BCI IV-2a, CR=64): we replace one band of the generalist reconstruction by the reconstruction of a specialist trained only on that band, and report the change in accuracy. A summary Table is below:
In motor imagery, the largest gain comes from α, with smaller effects for the other bands. A codec weighted towards β would therefore be tuned to one task and not to the other. Therefore, we keep band agnostic training for BioSQ and describe this finding in detail in Appendix E. This additional contribution suggested by the Reviewer may certainly improve task performance for practitioners and is of high interest.
W2. Related works
We thank the Reviewer for pointing out these highly relevant methods. Indeed, all three papers are interesting and we now include them in the Related Works section. We highlight in the Table below the key similarities and differences with our BioSQ:
See the rest of the response in the following comment.